Estrogen treatment for acromegaly

Ilan Shimon*, Ariel Barkan

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Estrogens have been used in patients with acromegaly since the 1930-1940s, suppressing plasma IGF-1 levels and improving clinical signs and symptoms of acromegaly. Estrogens antagonize GH function at the post-receptor level, inhibiting GH signaling, thus decreasing GH-induced hepatic IGF-1 synthesis. We report our experience with four female patients with active acromegaly, naïve to medical treatment or inadequately controlled by somatostatin receptor ligands (SRLs) or the GH-receptor antagonist. Adding estrogen treatment (contraceptive pills or transdermal estrogen patches) to their ongoing medical treatment, suppressed IGF-1 significantly in all patients, achieving hormonal remission in three of them. We review the available data on the use of estrogens and selective estrogen receptor modulators in acromegaly, and their mechanisms of action. Estrogens could be an alternative, inexpensive adjuvant treatment for females with active acromegaly, who are only partially responding to SRLs or to the GH-receptor antagonist.

Original languageEnglish
Pages (from-to)601-607
Number of pages7
Issue number4
StatePublished - Dec 2012


  • Acromegaly
  • Estrogen
  • IGF-1
  • Selective estrogen receptor modulators
  • Somatostatin receptor ligands


Dive into the research topics of 'Estrogen treatment for acromegaly'. Together they form a unique fingerprint.

Cite this